Introduction: P-Glycoprotein (ABCB1, MDR1) is a multidrug efflux pump that is a member of the ATPbinding cassette (ABC) superfamily. Many drugs in common clinical use are either substrates or inhibitors of this transporter. Quantitative details of P-glycoprotein inhibition by pharmaceutical agents are essential for assessment of their pharmacokinetic behavior and prevention of negative patient reactions. Cell-based systems have been widely used for determination of drug interactions with P-glycoprotein, but they suffer from several disadvantages, and results are often widely variable between laboratories. We aimed to demonstrate that a novel liposomal system employing contemporary biochemical methodologies could measure the ability of clinically used drugs to inhibit the P-glycoprotein pump. To accomplish this we compared results with those of cell-based approaches. Methods: Purified transport-competent hamster Abcb1a Pglycoprotein was reconstituted into a unilamellar liposomal system, Fluorosome-trans-pgp, whose aqueous interior contains fluorescent drug sensors. This provides a well-defined system for measuring Pglycoprotein transport inhibition by test drugs in real time using rapid fluorescence-based technology. Results: Inhibition of ATP-driven transport by Fluorosome-trans-pgp employed a panel of 46 representative drugs. Resulting IC 50 values correlated well (r 2 = 0.80) with K d values for drug binding to purified P-glycoprotein. They also showed a similar trend to transport inhibition data obtained using LLC-MDR1 cell monolayers. Fluorosome-trans-pgp IC 50 values were in agreement with published results of digoxin drugdrug interaction studies in humans. Discussion: This novel approach using a liposomal system and fluorescence-based technology is shown to be suitable to study whether marketed drugs and drug candidates are P-glycoprotein inhibitors. The assay is rapid, allowing a 7-point IC 50 determination in b 6 min, and requires minimal quantities of test drug. The method is amenable to robotics and offers a cost advantage relative to conventional cell-based assays. The well-defined nature of this assay also obviates many of the inherent complications and ambiguities of cell-based systems.
Introduction
Several mammalian members of the ATP-binding cassette (ABC) superfamily of proteins function as multidrug efflux pumps (Eckford & Sharom, 2009 ). These proteins not only serve to protect the organism from potentially toxic xenobiotics, but also play an important role in the absorption and distribution of drugs used in clinical therapy (Leslie, Deeley, & Cole, 2005) . Of the ABC multidrug transporters, P-glycoprotein (Pgp; ABCB1, MDR1) is the most studied, and the one we know most about in terms of its structure and mechanism of action. Pgp substrates vary widely in their molecular structure, although most are 300-1000 Da in size, amphipathic and relatively non-polar, often with aromatic rings and a positive charge at physiological pH. Substrates of Pgp are transported out of the cell in an ATPdependent fashion, and in vitro studies have shown that this transport is active and takes place against a chemical gradient of substrate concentration (reviewed in Sharom, 1997) . Pgp is localized in the apical plasma membrane of intestinal epithelial cells, where it limits entry of substrates from the gut lumen, and at the apical surface of endothelial cells in the capillaries of the brain (Eckford & Sharom, 2009 ).
Here, it forms a major component of the blood-brain barrier, impeding the entry of substrates into the central nervous system. Studies on Pgp knockout mice have confirmed the physiological role of Pgp in these tissues, and have also been useful in assessing how the transporter handles many pharmacological agents (Schinkel, 1998) .
Pgp inhibitors (also known as modulators) also interact with the protein, but they block the transport process. Inhibitors share many of the chemical properties of transport substrates, and are also structurally diverse. Many drugs in common clinical use are either substrates or inhibitors of Pgp, including anticancer drugs, calcium channel blockers, HIV protease inhibitors, calmodulin antagonists, anti-histamines, analgesics, steroids, antibiotics, and immunosuppressive agents (for a more detailed list, see Eckford & Sharom, 2009; Sharom, 2008) . Because of the involvement of Pgp in the intestinal absorption and tissue distribution of these drugs, their effectiveness may be adversely affected by interaction with the transporter. In addition, pharmacokinetic interactions between two drugs that both interact with Pgp can be a serious problem potentially leading to toxic side effects in patients. Because a large number of pharmaceutical agents interact with Pgp, it is important to test new drugs for such interactions and also to establish whether existing drugs in clinical use are substrates or inhibitors of the transporter. The U.S. Food and Drug Administration now recommends that Pgp-interactions be documented as part of the drug approval process (Giacomini et al., 2010) . Attempts have been made to develop pharmacophores for Pgp, however, experience has shown that, at best, these work within a structural series, and that extrapolations to structurally unrelated compounds are not possible. Therefore, reliance on in silico approaches to determine whether compounds are substrates or inhibitors of Pgp is not currently feasible. This emphasizes the need for the development of higher throughput experimental assays, as exemplified in the present manuscript.
A large number of in vitro and cultured cell-based assays have been developed for assessing the interaction of drugs with Pgp (for a review, see Sharom & Siarheyeva, 2008) . Many of these methods are based on inhibition of transport of a reference compound by the test drug, to produce an IC 50 value. Each of the methods in current use has shortcomings, and a combination of approaches is often needed to unambiguously identify Pgp substrates and inhibitors. Methods based on polarized epithelial cell monolayers are widely used, and considered the "gold standard" in the pharmaceutical industry. Yet these assays are expensive, time-consuming, and labor-intensive (Polli et al., 2001) . All cell lines express other drug transporters in addition to Pgp (Acharya et al., 2008) , and sometimes carry out metabolism of the test drug, making interpretation of results more difficult. Also, as described in the Discussion section of this paper, the IC 50 values obtained from cell-based assays are often highly variable between laboratories.
In this work, we sought to demonstrate that a novel experimental approach utilizing contemporary biochemical methodology incorporating highly purified, functionally reconstituted Pgp into liposomal particles with fluorescent sensor molecules in their interiors can quantitate inhibition of Pgp-mediated transport by test drugs in real time. We also evaluated whether measured IC 50 values for a panel of 46 drugs using this in vitro system correlate with the affinity of these compounds for binding to purified Pgp, and whether the results for a subset of these compounds are similar to those obtained from cell monolayer experiments. The IC 50 values are also correlated with in vivo published data on drug interactions with digoxin.
Materials and methods

Materials
Hamster Abcb1a Pgp was purified from plasma membrane vesicles of the multidrug-resistant cell line CH R B30, as previously described (Liu, Siemiarczuk, & Sharom, 2000) . The final product was 90-95% pure protein in 2 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), with ATPase activity in the range 1.5-2.1 μmol/min per mg protein, as determined by an assay described earlier (Chifflet, Torriglia, Chiesa, & Tolosa, 1988; Eckford & Sharom, 2006 LLC-PK1 cells (controls) and LLC-PK1 cells expressing a cDNA encoding human MDR1 Pgp (LLC-MDR1) were obtained from the Netherlands Cancer Institute (Amsterdam). The cells were maintained in Medium 199 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (50 units/mL) and streptomycin (50 μg/mL). Cells were maintained at 37°C in an atmosphere of 95% air/5% CO 2 and 90% relative humidity.
Purification and reconstitution of Pgp
Protein was determined by the method of Bradford (Bradford, 1976) . Purified Pgp was reconstituted into proteoliposomes of egg phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) at a lipid: protein ratio of~10:1 (w/w) using detergent removal by Sephadex G50 gel filtration chromatography (Romsicki & Sharom, 2001 ). Proteoliposomes were stored in aliquots at − 80°C in HEPES buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl 2 , pH 7.4) containing 2 mM dithioerythritol.
Measurement of drug binding affinity of Pgp
The drug (test compound) binding affinity of Pgp in CHAPS micelles was measured using either saturable quenching of the intrinsic Trp fluorescence of the protein (Liu et al., 2000) , or saturable quenching of 2-(4-maleimidoanilino)naphthalene-6-sulfonic acid (MIANS)-labeled Pgp (Liu & Sharom, 1996) . Fluorescence titration data were fitted to an equation describing binding to a single site, and the dissociation constant, K d , for binding of drug was estimated. No binding curves were obviously biphasic, and all fitted well to a single site model.
Fluorosome-trans-pgp production
Fluorosome-trans-pgp (Fl-t-pgp) was manufactured by the extrusion of purified reconstituted Pgp in HEPES buffer in the presence of bovine serum albumin (BSA)-fluorescein (Molecular Probes, Eugene, OR), resulting in unilamellar vesicles of~200 nm diameter. Nonencapsulated BSA-fluorescein was removed by ultracentrifugation and Sepharose 6B gel-exclusion chromatography. Fl-t-pgp reagent consists of Fl-t-pgp in HEPES buffer (1 mg/mL) pre-incubated for a minimum of 5 min with 0.5 μM of the model transport substrate S-HR (The Fluorosome Company, Worcester, MA).
Fluorosome-trans-pgp assay
Liquid handling employed a Solo High-Throughput Single Channel Pipettor (Hudson Robotics, Springfield, NJ). Fl-t-pgp reagent (98 μL per well) was aliquoted into 96-well, half-well fluorescence microplates, and the plate was loaded into a NOVOStar microplate reader (BMG LABTECH, Durham, NC). Measurements were made at 23°C in well mode with fluorescence excitation at 485 nm and emission monitored at 520 nm. For each well, fluorescence was initially measured for 20 s to establish a baseline, then the Pgp pump was activated by rapidly injecting 5 μL of a stock solution of ATP in HEPES buffer using the NOVOStar onboard micropipettor, resulting in a final ATP concentration of 2 mM. The injection resulted in an immediate downward drop in fluorescence, which is an instrumental injection artifact (Jarrett Cheek, BMG LABTECH, personal communication). Fluorescence was monitored for an additional 40 s, with Pgp transport activity taken as the slope from 10 to 40 s after ATP injection. A flat baseline was observed when ATP was injected in the presence of 300 μM of the ATPase inhibitor sodium orthovanadate or when the non-hydrolyzable ATP analog adenosine 5′-( β,γ-imido)triphosphate (AMP-PNP, 2 mM final concentration) was injected, after the immediate artifactual drop in fluorescence.
Fluorosome-trans-pgp inhibition measurements
Inhibition measurements were made by adding 2 μL aliquots of test compound (drug) solutions in DMSO to 98 μL aliquots of reagent in the wells of 96-well, half-well fluorescence microplates. Reference (control) wells had 2 μL of DMSO added to them. The microplates were shaken to ensure thorough mixing, and, after 5 min to establish equilibrium, the plate was loaded into the NOVOStar microplate reader. Fluorescence acquisition and initiation of transport were done as described above. All transport inhibition experiments were carried out at least twice. Slopes were calculated using BMG's onboard Mars software, and IC 50 values were calculated using Prism Software (Graphpad Software, San Diego, CA) by fitting the Pgp transport activity (slope) at each test compound concentration to a robust fit for a one-phase decay. The IC 50 value was calculated from this fit as that drug concentration causing 50% inhibition of Pgp transport activity. Similar results were obtained when the assay was performed in 384-well plates using starting volumes of 20-50 μL.
LLC-MDR1 inhibition measurements
Measurements were made as described previously (Reitman et al., 2011) . Briefly, the LLC-MDR1 and control cell lines were cultured in 24-well trans-well culture plates (Millipore, Billerica, MA). [ 3 H]Digoxin (0.1 μM) and inhibitors were prepared in transport buffer (Hanks buffer with 10 mM HEPES, pH 7.4). Prior to the transport study, cells were washed three times with transport buffer. [ 3 H]Digoxin substrate solution (500 μL) was added to either the apical (A) or basolateral (B) compartment of the culture plate, and buffer (500 μL) was added to the opposite compartment. Inhibitor (test compound) was added to both compartments. After 3 h incubation at 37°C, 50 μL samples were taken from both sides, and 200 μL of scintillant was added. Radioactivity was determined by liquid scintillation counting in a MicroBeta Trilux scintillation counter (Perkin Elmer; Boston, MA). All experiments were performed in triplicate.
Percentage of transport was calculated by dividing the concentration of digoxin measured in the receiver compartment by the sum of the concentrations measured in the receiver and donor compartments. Net transport of digoxin in LLC-MDR1 cells was calculated according to Eq. (1):
Percent control transport in the presence of an inhibitor was calculated according to Eq. (2):
where R I represents net transport of digoxin measured in the presence of various concentrations of inhibitor, and R o represents the net transport of digoxin in the absence of inhibitor. Prior to the actual assay, the pgp substrate S-HR is introduced into a preparation of Fl-t-pgp and passively diffuses through the membrane to reach a state of equilibrium. Upon entering the aqueous interior of the Fl-t-pgp particle, the substrate rapidly binds to the fluorescent sensor, resulting in a new and stable fluorescence baseline (not shown). 1. To conduct a transport assay, "Fl-t-pgp reagent" in the wells of a microplate is placed in a fluorescence plate reader, and measurement is initiated. 2. ATP is injected. 3. Substrate is actively pumped by Pgp against a concentration gradient into the interior of the Fl-t-pgp particle, and the influxed substrate is rapidly bound by the encapsulated fluorescent sensor. 4. A linear, time-dependent alteration of the fluorescence intensity is observed.
IC 50 values for inhibition of Pgp-mediated [ 3 H]digoxin transport were obtained by fitting the data to Eq. (3) by nonlinear regression analysis using Kaleidagraph software (KaleidaGraph Synergy Software, Reading, PA):
where I is the inhibitor concentration (μM) and s is the Hill slope.
Statistics
Correlations between data sets were calculated using Prism assuming Gaussian (Pearson) populations.
Results
Preparation and characterization of Fluorosome-trans-pgp
The introduction of new technology makes it possible to quantitate the interaction of Pgp with its substrates in a fully defined in vitro system. Fl-t-pgp consists of synthetic unilamellar lipid vesicles manufactured as described in the Materials and methods. The Fl-t-pgp bilayer membrane is composed of egg phosphatidylcholine and contains highly purified functional Pgp (Liu et al., 2000) , reconstituted such that its ability to transport substrates is retained (Lu, Liu, & Sharom, 2001) . Purified Pgp had high levels of ATPase activity (~1 μmol/min/mg) and previous work indicated that, following reconstitution, the protein displayed >40% of the drug transport activity it possessed in the native membrane vesicles from which it was purified (Sharom et al., 1993) . A single Fluorosome particle contains approximately 1700 Pgp molecules, about half of which are expected to be oriented in an inside-out direction, with their nucleotide binding domains accessible on the outer surface of the lipid vesicle (Romsicki & Sharom, 1997) . The Fl-t-pgp study described here utilized the Pgp model substrate S-HR, which has a K d of 0.27 μM for binding to Pgp and interacts with both the H and R sites of the transporter. The latter properties are consistent with the compound's IC 50 values of 0.9 μM for H33342 transport (H-site) and 0.7 μM for tetramethylrosamine transport (R-site) (B. Vinepal and F.J. Sharom, unpublished data). The aqueous interior of the Fl-t-pgp particle contains the fluorescent sensor BSA-fluorescein. In solution, BSAfluorescein binds S-HR, with a resulting change in fluorescein emission intensity, apparently due to a combination of static and dynamic fluorescence probe/substrate interactions, as indicated by life-time fluorescence studies (The Fluorosome Company, unpublished results).
The principle of operation of the Fl-t-pgp assay is illustrated in Fig. 1 . Prior to the actual assay, the Pgp probe substrate S-HR is introduced into a preparation of Fl-t-pgp and passively diffuses through the Fl-t-pgp membrane to reach a state of equilibrium. Upon entering the aqueous interior of the Fl-t-pgp particle, the probe substrate rapidly binds to the fluorescent sensor, resulting in a new and stable fluorescence baseline (not shown). For a measurement, this "Fl-t-pgp reagent", aliquoted into the wells of a microplate, is placed in a fluorescence plate reader and the measurement initiated (step 1). After 20 s to ensure a stable baseline, ATP is injected (step 2). Substrate is then actively pumped by Pgp into the interior of the Fl-t-pgp particle, and the influxed substrate is rapidly bound by encapsulated sensor (step 3), resulting in a linear, timedependent alteration of the fluorescence intensity (step 4). The screenshot in Fig. 2 demonstrates the result of a typical assay in the absence and presence of varying concentrations of the Pgp inhibitor cyclosporin A.
The added ATP activates only those Pgp molecules with their nucleotide binding sites facing the external solution. Proteins with the opposite orientation are non-functional in terms of transport, because the bilayer membrane is impermeable to ATP. Hydrolysis of ATP results in the active pumping of S-HR into the aqueous interior of the Fl-t-pgp particle, with concomitant changes in the fluorescence intensity of the sensor encapsulated in the vesicle lumen. No change in sensor fluorescence was observed in the presence of ATP together with the ATPase inhibitor orthovanadate, or when the non-hydrolyzable analog AMP-PNP was used, confirming that transport was driven by ATP hydrolysis. Thus the change in fluorescence emission intensity of the sensor with time is a direct monitor of the rate of Pgp transport of S-HR. Flt-pgp suspensions containing inhibitors in the absence of the substrate S-HR gave no time-dependent changes in fluorescence upon injection of ATP. Substrate transport by Fl-t-pgp has the important advantage that the only transporter present is Pgp, whereas additional drug transporters are expressed endogenously in the plasma membrane of cultured cells.
Inhibition of Pgp-mediated drug transport by Fluorosome-trans-pgp
Fl-t-pgp provides a direct measurement of Pgp activity in the presence of test compounds, thus allowing the direct determination of percent inhibition at any concentration of test compound, and IC 50 values by measuring inhibition at varying concentrations of test compound. An example of real-time experimental determination of inhibition of Pgp activity by a drug is presented in Fig. 2 , which shows the time course of ATP-dependent fluorescence emission by Fl-t-pgp reagent in the absence and presence of several concentrations of cyclosporin A, an established inhibitor of Pgp. The ratio of the slope for a kinetic run containing cyclosporin A to the slope of a run in its absence (control) gives the fractional reduction in Pgp transport activity at that concentration of cyclosporin A. Changes in fluorescence due to interaction of test compounds with the sensor are negligible and do not contribute to the observed slope.
The reproducibility of IC 50 values obtained by the Fl-t-pgp technique is exemplified by 7 experiments with cyclosporin A carried out over a period of 14 months using three different types of fluorescence plate readers; the average IC 50 value was 0.58 μM with a standard error of 0.06 μM (10%).
When test compounds are added to the Fl-t-pgp reagent before the injection of ATP, Pgp inhibitors reduce the rate of ATP-dependent transport of the substrate into the interior of the Fl-t-pgp particle, seen as a decrease in the rate of change (slope) of the fluorescence signal. In this way, IC 50 values for inhibition of S-HR transport by Fl-t-pgp were determined for 46 test compounds (Table 1 ). The test compounds were drugs and drug candidates representing numerous therapeutic areas (anticancer drugs, HIV protease inhibitors, peptides, statins, β-blockers, ACE inhibitors, antidepressants, antifungal agents, antiparasitic agents, calcium channel blockers, and anti-gout medications). Their IC 50 values cover a range of over three orders of magnitude, and representative inhibition plots for 6 of these compounds with IC 50 values ranging from 0.1 μM to 516 μM are shown in Fig. 3 . It should be noted that those compounds developed as Pgp inhibitors, e.g. tariquidar, elacridar, valspodar, and zosuquidar, show very low IC 50 values, as does the classic Pgp inhibitor cyclosporin A. Among the less potent inhibitors is digoxin, a common substrate for cell-based assays (see also below), and its corresponding aglycone, digoxigenin.
Relationship between transport inhibition and binding affinity to Pgp
Substrate transport by Pgp is a complex multistep process (Callaghan, Ford, & Kerr, 2006) , and details of the kinetics of the various steps involved remain elusive. Because an inhibitor (test compound) may compete with substrate for binding to Pgp in order to inhibit its transport and may itself be transported, the affinity of Pgp for binding a particular test compound should be closely related to its measured IC 50 value for inhibition of substrate transport. To explore this relationship, Pgp binding affinities were determined using previously established fluorescence approaches. For example, test compound binding to purified Pgp in CHAPS micelles in solution leads to saturable quenching of the protein's intrinsic Trp fluorescence (Liu et al., 2000) , or quenching of an extrinsic fluorescent probe (MIANS) covalently linked to the protein via a cysteine residue (Liu & Sharom, 1996) . Of the 46 compounds tested with Fl-t-pgp, K d values were obtained for 33; these values are listed in Table 1 . The remaining compounds were either autofluorescent and thus interfered with the assay, or did not produce high enough maximal quenching for accurate K d estimation. A log-log plot of Fl-t-pgp IC 50 values vs. Pgp K d values for the corresponding compounds is shown in Fig. 4 . The correlation (r 2 ) was 0.80. This suggests that the ability of a test compound to inhibit Pgp-mediated transport of substrate is indeed in general related to its binding affinity. It should be noted that this correlation extends over four orders of magnitude, from IC 50 values in the nM range (tariquidar, 21 nM) to the mM range (digoxigenin, 0.52 mM). A few compounds (zosuquidar, paclitaxel) have an IC 50 value substantially higher than the K d value, however, other compounds have an IC 50 value substantially lower than the K d value, e.g. nicardipine, nifedipine, elacridar. It is not easy to explain these differences for individual test drugs, especially since the mechanisms by which they inhibit Pgp are unknown. The different assay systems used to measure IC 50 and K d (liposomes vs. purified protein in detergent solution) may account for the less than perfect correlation between the two parameters.
Inhibition of Pgp-mediated drug transport in LLC-MDR1 cell monolayers
In order to compare inhibition data from the Fl-t-pgp system with those from an intact cell assay system, cultured monolayers of LLC- Table 1 . In general, the results of the cell-based assay parallel those derived from Fl-t-pgp. A log-log plot of cell-based IC 50 values with those derived from Fl-t-pgp is shown in Fig. 6 . The data sets have a correlation (r 2 ) of 0.994. The IC 50 values measured in LLC-MDR1 cells were systematically higher than those measured using the Fl-t-pgp system (Table 1) . This trend may be caused by the differences between an in vitro vesicle-based system and a cell-based system, or they could arise from differences in drug interactions or the mechanism of inhibition between rodent and human Pgp. Since the trend is systematic, it seems more likely that it arises from the first possibility. Intact cell systems have an inherent tendency to adsorb or bind drugs non-specifically, which would lower the amount of drug available to interact with Pgp, thus requiring a higher concentration to observe inhibition.
Correlation of Fluorosome-trans-pgp results with digoxin-drug interaction data
Further investigation of the Fl-t-pgp inhibition assay was carried out by correlating IC 50 values with in vivo data for the effects of various co-administered second drugs ("inhibitors") on the area under the curve (AUC) after oral administration and maximum plasma levels at steady state (C max,ss ) of digoxin in human patients. Relevant data for digoxin, AUC and AUC I and C max,ss and C max,ss,I , in the absence and presence of inhibitor I, respectively, were taken from Fenner et al. (Fenner et al., 2009) 
Discussion
In this work, we report the preparation of a novel reagent, and demonstrate its utility as an in vitro method to screen drugs and other test compounds for inhibition of the important drug efflux transporter Pgp. Incorporation of purified mammalian Pgp into a lipid bilayer vesicle containing a fluorescent sensor in the aqueous interior -Fl-t-pgp -affords a specific assay for measuring interaction of test compounds with the transporter in real time. The Fl-t-pgp reagent makes use of rodent (hamster) Pgp rather than human Pgp, because extensive studies of the former protein over many years have indicated that it has high ATPase and drug transport activity, and is sufficiently robust for development of such an assay reagent. In contrast, purified human Pgp proved to be too unstable for production of a reconstituted vesicle system that can maintain drug transport function over a period of several days (F.J. Sharom, unpublished data). It should be noted that the recent crystal structure of Pgp was determined using the mouse protein (Aller et al., 2009 ) for similar reasons. Hamster Pgp (Abcb1a) is very closely related to the human protein, with 87% amino acid sequence identity and 93% similarity. Indeed, the transmembrane regions of the two proteins where the drug-binding pocket is located show an even greater degree of similarity/identity and the important residues involved in substrate binding are highly conserved (Aller et al., 2009 ). Species differences in drug transport specificity between rodent and human Pgp observed in cell-based assays are small, and may be artifacts arising from assay format, different expression levels and transport substrates (Booth-Genthe et al., 2006; Zolnerciks, Booth-Genthe, Gupta, Harris, & Unadkat, 2011) , as well as differences in expression of other drug transporters (Acharya When 3300 Pfizer compounds were tested in human MDR1-MDCK and mouse Mdr1a-MDCK trans-well assays, a very good correlation was observed (R 2 = 0.92) between the efflux ratios in MDR1-MDCK and Mdr1a-MDCK cells (Feng et al., 2008) . This group concluded that mouse Pgp is a useful model to predict human Pgp activity in vivo. The ABCB1-transfected cell lines currently used for identification of Pgp substrates are also not ideal models, because the activity and specificity of Pgp may vary with expression level and host cell type. Human Pgp in different tissues (e.g. intestine vs. blood brain barrier) may also display variations in activity and specificity, so that exactly mimicking the in vivo situation in an in vitro assay system is not possible.
Compounds that interact with Pgp may be substrates and/or inhibitors. The Fl-t-pgp assay identifies both types of compounds without distinction, because it is based on competition/inhibition of transport of a probe substrate. It is still not clear how Pgp inhibitors act at the molecular level. Some of these compounds (e.g. verapamil, cyclosporin A) are themselves transported, and clearly compete with substrates for binding to Pgp (reviewed in Sharom, 1997) . However, others (e.g. zosuquidar/LY335979) display prolonged high affinity binding to the protein (Starling et al., 1997) , suggesting that some inhibitors block transport by interacting very tightly with the substrate binding pocket of Pgp. The recent X-ray crystal structure of Pgp (Aller et al., 2009) , as well as several biochemical studies (Loo, Bartlett, & Clarke, 2003; Lugo & Sharom, 2005) , indicate that the protein contains a large flexible multi-site binding pocket that can accommodate at least two drug molecules simultaneously in distinct sub-sites. It was shown earlier that two major functional transport sub-sites exist; one (the H-site) transports Hoechst 33342 (bisbenzimide), the other (the R-site) transports the fluorescent dye, rhodamine 123 (Shapiro & Ling, 1997) . Steric and allosteric interactions between these sub-sites result in one drug having either stimulatory or inhibitory effects on transport of a second drug, and led to the proposal of a complex interaction network between them (Martin et al., 2000) . How interactions between drugs at the level of transport are related to the structure of the Pgp binding pocket in molecular terms is not well understood. However, the location of two pseudo-symmetric translocation pathways through the protein has recently been reported (Parveen et al., 2011) . The complication of multiple binding sites and the interactions between them has not really been addressed in cell-based assays for Pgp substrates and inhibitors (Zolnerciks et al., 2011) , and may require the use of several reference compounds, which is not practical where many drugs are to be tested. The Fl-t-pgp system lends itself to mechanistic studies of Pgp function. By varying the concentration of substrate as well as inhibitor, K i values for different drugs as well as the type of inhibition, e.g. competitive or non-competitive, can be investigated. This may shed further light on the clearly complex relationship between drug binding sub-sites.
Evidence that the Fl-t-pgp system is a true mimic of the transporter in cell membranes is afforded by the described results, which show that: 1) the assay responds to ATP, producing a linear change in fluorescence consistent with transport of the substrate S-HR (Fig. 2) ; 2) transport of the substrate depends on ATP hydrolysis; 3) IC 50 values of test compounds correlated well with K d , i.e. the binding affinity of the transporter for these compounds (Fig. 4) ; and 4) IC 50 values of test compounds are in a similar rank order and comparable in magnitude to those obtained by a conventional, cell-based method for a subset of the test compounds (Table 1) . It should be noted that the transport substrate S-HR used with the Fl-t-pgp system is able to interact with both the H-site and R-site of Pgp (B. Vinepal and F.J. Sharom, unpublished data) . This provides an advantage over other reference substrates, which in many cases have not been characterized for interactions with these sites.
There are several cell-based and vesicle-based methods currently in use to determine substrate and/or inhibitor properties of test compounds on Pgp (Sharom & Siarheyeva, 2008 Table 1 ) or other radiolabeled compounds are used, often at different concentrations. The lack of agreement between results obtained using different cell-based systems, as well as between results obtained using the same system in different laboratories (see below), as well as variations in mathematical processing of assay data, create uncertainty in the validity of these results. The requirement for sterile conditions to maintain and grow cells, the cumbersome and time-consuming assay conditions, and the need for acquiring and handling of radioactive substrates, further complicate the use of cell-based methodologies.
The wide variation in reported IC 50 values for Pgp inhibitors is a confounding factor in interpretation of drug-drug interaction data. A review of published results on several of these compounds (designated by the International Transporter Consortium to be employed as "selected inhibitors" of Pgp; see Giacomini et al., 2010) , obtained using a variety of celland vesicle-based assays and employing various test substrates, reveals the following variations in IC 50 values: tariquidar, 60.5-fold (Dickens, Owen, Alfirevic, & Pirmohamed, 2009; Höcheri, 2010; Klinkhammer, Muller, Globisch, Pajeva, & Wiese, 2009; Weiss & Haefeli, 2006) , cyclosporin A, 12.4-fold (Dickens et al., 2009; Klinkhammer et al., 2009; Rautio et al., 2006 (Fenner et al., 2009; Dickens et al., 2009; Klinkhammer et al., 2009; Rautio et al., 2006 ; U.S. Department of Health and Human Services Food and Drug Administration (FDA) Fig. 6 . Plot (log-log) of the IC 50 values for transport inhibition determined using LLC-MDR1 cell monolayers and IC 50 values for transport inhibition determined using the Fl-t-pgp assay for 16 test compounds. (Fenner et al., 2009) . b Estimated gastrointestinal concentration of drug ("inhibitor") after oral dose, in μM; data taken from Fenner et al. (Fenner et al., 2009 ). c Half-maximal concentration for inhibition of transport in Fl-t-pgp by drug ("inhibitor"), in μM.
(2006); Weiss & Haefeli, 2006 ) (see also Lee, 2011) . The significant variations in IC 50 values underscore the need for simple and robust assays to give accurate inhibitor information for pgp (and related transporters). With additional studies, the Fl-t-pgp assay described in this work may prove to be valuable in this regard. The ultimate test of an assay is whether its results accurately correlate with real properties of drugs in human patients. Fenner and coworkers (Fenner et al., 2009 ) provided a novel approach to this problem by correlating published effects of drugs on digoxin levels in human patients with parameters of their inhibition of Pgp. Our use of potencies of drugs (inhibitors) derived from Fl-t-pgp assays (Table 2) showed at least equivalent, if not superior, correlations with digoxin disposition (Fig. 7a-d) . To make effective use of the IC 50 values determined using the Fl-t-pgp assay, they will need to be compared to relevant drug exposure levels in vivo. For example, drug concentrations in the gut will be substantially higher than those in the plasma. The current guidance published by the International Transporter Consortium indicates how to establish the clinical relevance of in vitro data of the type presented in this study (Giacomini et al., 2010) .
Summary
We have created for the first time a transporter assay system that enables definitive measurement of Pgp activity and its inhibition in real time. We have demonstrated that for a large panel of test compounds (drugs) IC 50 values resulting from this assay are consistent with their binding affinities to Pgp and are in agreement both with data from cell monolayer-based assays and published results of human drug-drug interaction studies using digoxin. Fl-t-pgp is the first of a series of drug transporter-lipid vesicle constructs that can be used for high-throughput screening of drugs and potential drug candidates, and for research into the mechanisms of substrate transport and drug-drug interactions. Since the studies described above, we have been able to employ the Fluorosome assay in 384-well microplates using a starting volume of Fl-t-pgp reagent as low as 20 μL, thereby decreasing the amount of test drug required to carry out the assay, and its concomitant cost. The Fluorosome platform is simple in application, offers fast turnover (40 s per data point; a 7-point IC 50 can be determined in b6 min), gives real-time measurements with immediate results, and is Plot of the ratio of C max for digoxin in the presence and absence of drug (inhibitor) vs. the ratio of peak plasma concentration of drug (inhibitor) and the IC 50 for Fl-t-pgp. (d) Plot of the ratio of C max for digoxin in the presence and absence of drug (inhibitor) vs. the ratio of gastrointestinal concentration of drug (inhibitor) and the IC 50 for Fl-t-pgp. In vivo data are taken from Fenner et al. (Fenner et al., 2009). fully amenable to robotics, allowing rapid throughput. It uses very small quantities of test drug, and since it employs minimal instrumentation, minimal labor and has no requirement for sterility, is a cost-effective approach relative to cell culture methodologies. The well defined nature of this platform also obviates many of the inherent complications and ambiguities inherent in cell-based systems.
